Latest filing published 11 Jun 2026 for Atara Biotherapeutics, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Filings by William K. Heiden span 2 companies, the busiest being Atara Biotherapeutics, Inc. and Macrogenics Inc. Between 8 June 2021 and 9 June 2026, the trades on record add up to 10 filings.
Every open-market trade on record is a purchase: 2 purchases worth €90k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 6 share grants and 2 option exercises.
The latest filing, published on 11 June 2026, reports a share grant in Atara Biotherapeutics, Inc. The last insider purchase was made public on 21 August 2025, 423 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations